Table 3. Univariate and multivariate analysis results of all laboratory tests by group.
| Variable | Normal group (n=100) | Abnormal group (n=28) | Univariate | Multivariat | ||
|---|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |||
| Age (yr) | 41.48±14.11 | 42.25±15.89 | 1.001 (0.975~1.027) | 0.955 | ||
| Sex | ||||||
| Male | 48 (48.0) | 23 (82.1) | 0.217 (0.073~0.527) | 0.002* | 0.225 (0.075~0.550) | 0.003* |
| Female | 52 (52.0) | 5 (17.9) | ||||
| BMI (kg/m2)† | 23.77±3.94 | 25.98±3.77 | 1.176 (0.974~1.433) | 0.094 | ||
| Duration of disease (mo) | 100.95±110.35 | 75.71±80.01 | 0.997 (0.993~1.001) | 0.178 | ||
| PASI score‡ | ||||||
| ≤10 | 35 (40.2) | 8 (32.0) | 1.009 (0.971~1.044) | 0.633 | ||
| >10 | 52 (59.8) | 17 (68.0) | ||||
| Total medication period (d) | 308.90±350.60 | 380.00±289.45 | 0.999 (0.997~1) | 0.111 | ||
| Cumulative dose (g) | 42.55±44.00 | 57.37±39.11 | 1 (1~1) | 0.240 | ||
| Underlying diseases | ||||||
| Diabetes | 7 (7.0) | 1 (3.6) | 2.195 (0.462~39.301) | 0.442 | ||
| Hypertension | 13 (13.0) | 1 (3.6) | 3.611 (0.767~64.449) | 0.208 | ||
| Dyslipidemia§ | 9 (9.0) | 0 (0.0) | 6.025 (0.843~763.957) | 0.217 | ||
| Chronic hepatitis B infection | 2 (2.0) | 1 (3.6) | 1.046 (0.220~18.751) | 0.965 | ||
| Kidney disease | 0 (0.0) | 1 (3.6) | 0.049 (0.008~0.924) | 0.005* | 0.076 (0.013~1.447) | 0.018* |
| Others∥ | 7 (7.0) | 2 (7.1) | 0.825 (0.245~5.136) | 0.794 | ||
Values are presented as mean±standard deviation or number (%). BMI: body mass index, PASI: psoriasis area and severity index, HR: hazard ratio, CI: confidence interval. *p<0.05. †Including only patients for whom BMI (total=57, normal=44, abnormal=13) was available. ‡Including only patients for whom PASI score (total=112, normal=87, abnormal=25) was available. §Firth's correction was applied. ∥Angina, aortic dissection, autism, brain hemorrhage, stroke, thyroid disease.